Previous 10 | Next 10 |
Navidea Biopharm press release (NYSE:NAVB): Q4 GAAP EPS of -$0.12. Revenue of $0.05M (-77.3% Y/Y). cash and cash equivalents of $4.2M For further details see: Navidea Biopharm GAAP EPS of -$0.12, revenue of $0.05M
Conference Call to be held Wednesday, March 23, 2022 at 5:00 pm (EST) Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeu...
Conference Call to be Held on Wednesday, March 23, 2022 at 5:00 p.m. (EDT) Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunothe...
The FDA's rejection on Thursday of a citizen petition related to Cassava Sciences' (NASDAQ:SAVA) experimental Alzheimer's treatment simufilam has rekindled a long-time debate over how the petitions are being used by some, especially rival companies and those with deep pockets. The abilit...
Navidea Biopharmaceuticals (NYSE:NAVB) is trading ~20% higher on Monday after announcing that the company and the University of Pennsylvania entered into a sponsored research agreement to evaluate the potential of Tc99m tilmanocept imaging as a prognostic marker in glioblastoma. Acc...
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the signing of a Sponsored Research Agreement with the Unive...
Navidea Biopharmaceuticals (NYSE:NAVB) announced on Thursday that it received a letter from the NYSE American stating that the company has failed to comply with the continued listing standards of the stock exchange. The company is required to submit a plan on regaining compliance by Feb. 27, ...
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced settlement of the ongoing litigation with Platinum-Montaur L...
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the launch of the NAV3-33 Phase 3 clinical trial titled ...
Navidea Biopharmaceuticals (NYSE:NAVB) announced the termination of a Stock Purchase Agreement executed by the company on Aug. 30, 2020. Per the terms of the deal, investors agreed to buy up to $25M worth of shares of the company’s common stock with a par value of $0.001 per share. The...
News, Short Squeeze, Breakout and More Instantly...
Navidea Biopharmaceuticals Inc. Company Name:
NAVB Stock Symbol:
NYSE Market:
Navidea Biopharmaceuticals Inc. Website:
Navidea Biopharmaceuticals , Inc. has completed an exploratory analysis of its Rheumatoid Arthritis Program Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic a...
Navidea Biopharmaceucitals, Inc. will present two proposals for vote in a virtual special meeting of shareholders to be held on July 8, 2024 Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a company focused on the development of pre...
Navidea Biopharmaceuticals, Inc. announced today the filing of Form 15 to voluntarily deregister and suspend SEC reporting obligations. The company maintains strategic focus on its Fix, Fund, Propel approach. Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the &...